Cancer Institute A national cancer institute
designated cancer center

Immune Reconstitution

Effectively managing the period of immune reconstitution following an allogeneic transplant is critical to patient outcome. To minimize the complications of graft vs. host disease, reconstitution must be slowed with immunosuppressive drugs to give the donor immune system sufficient time to acclimate to its new environment.

Program researchers are working to address the challenges of this transition by studying the mechanisms that control the education of the immune system. As part of this work, they are looking to identify natural immune controls, such as regulatory T cells, to supplement current immunosuppressive therapies.

Researchers are also working to find ways to speed the overall process of immune reconstitution to reduce the risk of opportunistic infection. Treatments based on vaccination, cell-based therapies and the use of cytokines to accelerate immune reconstitution are under investigation.

Program Researchers

Ann M. Arvin, MD

Janice (Wes) Brown, MD

Robert Negrin, MD

Peter Parham, PhD

Kenneth Weinberg, MD

 

Stanford Medicine Resources:

Footer Links: